Tasectan | noventure.com

Gastroenterology Pediatrics Barrier Technology News TASECTAN®

TASECTAN® launched in Croatia by JGL

Noventure is proud to announce the launch of TASECTAN® in Croatia by its partner company JGL, under the brand Normia Stop. TASECTAN® acts by forming a film which protects the intestinal mucosa, reducing the frequency and duration of diarrhea episodes in adults, children and infants. TASECTAN® is marketed in 40 countries with growing sales of more than two million packs per year (ex-factory, as reported by commercial partners). TASECTAN® is a class III medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments (CE 0373, Noventure SL).

Gastroenterology Event Business TASECTAN® GELSECTAN® TASECTAN® DUO XILAPLUS®

NeuroGASTRO 2019

NOVENTURE will be present at NeuroGASTRO 2019, in Lisbon, September 05 – 07, 2019.

Gastroenterology Pediatrics Scientific Publication TASECTAN®

Efficacy of gelatin tannate for acute diarrhea in children: a systematic review and meta-analysis.

Publication of a systematic review and meta-analysis on the efficacy of gelatin tannate in acute diarrhea in children. Aim: To investigate by meta-analysis the efficacy of gelatin tannate (GT), a mucosal barrier protector, in children with acute gastroenteritis. Conclusion: GT significantly (p < 0.01) reduced stool frequency at 12 h as well as the number of patients with diarrhea or liquid stools at 24 h (p < 0.01), compared with placebo. No adverse events were reported in any of the RCTs analyzed. The unique mechanism and lack of systemic absorption of GT make this device an interesting addition to the current armamentarium for treating acute gastroenteritis in children.